metastatic malignant solid neoplasm
Showing NaN - NaN of 8
Advanced Malignant Solid Tumor, Autoimmune Disease, Crohn Disease Trial in Canada, United States (Nivolumab)
Recruiting
- Advanced Malignant Solid Neoplasm
- +15 more
- Biospecimen Collection
- Nivolumab
-
Birmingham, Alabama
- +46 more
Jan 31, 2023
HER2-Positive Breast Carcinoma, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in United States
Recruiting
- Advanced Malignant Solid Neoplasm
- +4 more
- Biopsy
- +3 more
-
Bethesda, Maryland
- +4 more
Jan 21, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial in Canada,
Active, not recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +20 more
- Pembrolizumab
- Ziv-Aflibercept
-
Tampa, Florida
- +8 more
Jan 3, 2023
Advanced Pancreatic Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 Trial in
Recruiting
- Advanced Pancreatic Carcinoma
- +27 more
- Biopsy
- Talazoparib
-
Gainesville, Florida
- +3 more
Jan 3, 2023
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor Trial in United States (CDK Inhibitor
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- CDK Inhibitor AT7519
- +3 more
-
Washington, District of Columbia
- +5 more
Oct 18, 2022
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +3 more
- Pharmacodynamic Study
- Telaglenastat Hydrochloride
-
Birmingham, Alabama
- +30 more
Sep 1, 2022
Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Platinum-Resistant Ovarian Carcinoma Trial in
Recruiting
- Metastatic Malignant Solid Neoplasm
- +3 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
Bethesda, Maryland
- +4 more
Aug 16, 2022
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Tumor Trial run by the NCI (p97
Withdrawn
- Aggressive Non-Hodgkin Lymphoma
- +3 more
- p97 Inhibitor CB-5339 Tosylate
-
Bethesda, Maryland
- +1 more
Aug 27, 2021